Yantai Juxian Pharmaceutical Co Ltd.

The main purpose of the study is to study the pharmacokinetics of the test preparation brexpiprazole orodisintegrating tablets (specification: 2 mg) and the reference preparation brexpiprazole orodisintegrating tablets (Rexulti® OD Tablets, specification: 2 mg; certified by Otsuka Pharmaceutical Co., Ltd.) in healthy adult subjects after a single oral administration in the fasting/fed state, and to evaluate the bioequivalence of the two preparations when taken orally in the fasting/fed state. Secondary study objective: To observe the safety of the test preparation brexpiprazole orally disintegrating tablets and the reference preparation Rexulti® OD Tablets in healthy adult subjects.

The main purpose of the study is to study the pharmacokinetics of the test preparation of pediatric faropenem sodium granules 0.05 g and the reference preparation "Fei Luo Mu®" 0.05 g in healthy adult subjects after fasting and after meals, and to evaluate the bioequivalence of the test preparation of pediatric faropenem sodium granules and the reference preparation after fasting and after meals. Secondary purpose of the study: to study the safety of the test preparation of pediatric faropenem sodium granules 0.05 g and the reference preparation "Fei Luo Mu®" 0.05 g in healthy adult subjects.

This study investigated the relative bioavailability of a single oral dose of the test preparation indapamide tablets (2.5 mg/tablet) produced by Yantai Juxian Pharmaceutical Co., Ltd. and the reference preparation indapamide tablets (trade name: Natrilix®, 2.5 mg/tablet) produced by Les laboratoires Servier, France, under fasting conditions, evaluated the bioequivalence between the two preparations, and provided a basis for the consistency evaluation of the test preparation. The safety of a single oral dose of 2.5 mg of the test preparation indapamide tablets or the reference preparation Natrilix in healthy subjects was evaluated.